Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Genetic factors of an individual patient may have an impact on Ranibizumab (Lucentis)
treatment outcome in patients with Wet Age-Related Macular Degeneration (AMD).